Johnson & Johnson (JNJ) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 65
- Profitability 60
- Business Quality 80
- Balance Sheet 65
- Cash Flow 70
Why this rating?
Health 69/100 — High Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Johnson & Johnson (JNJ) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates Johnson & Johnson 69/100 (High Quality) due to high business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Moderate
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 40.78
- Forward P/E 23.13
- PEG 3
- EV/Revenue 6.79
Profitability
- Revenue Growth 5.9%
- Gross Margin 67.8%
- Operating Margin 25.7%
- Net Margin 16.2%
- ROE 20.0%
Financial strength
- Cash $17.23B
- Debt $44.65B
- Net Cash $-27.42B
- Free Cash Flow $19.31B
- Current Ratio 1.02
Similar companies
Peers in Drug Manufacturers - General, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Eli Lilly and Company Drug Manufacturers - General LLY$1,281.91 86 Health 86 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- AstraZeneca PLC Drug Manufacturers - General AZN$170.08 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Gilead Sciences, Inc. Drug Manufacturers - General GILD$159.08 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Biogen Inc. Drug Manufacturers - General BIIB$252.73 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- AbbVie Inc. Drug Manufacturers - General ABBV$286.39 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Bristol-Myers Squibb Company Drug Manufacturers - General BMY$61.55 72 Health 72 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Pfizer Inc. Drug Manufacturers - General PFE$29.80 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Amgen Inc. Drug Manufacturers - General AMGN$447.95 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
FAQ
How Compound Radar scores and tracks Johnson & Johnson (JNJ).